OpenLB
Open Library of Bioscience
Advanced Search
PloS one
2016;11 (8): e0161007.

Differential Expression Pattern of THBS1 and THBS2 in Lung Cancer: Clinical Outcome and a Systematic-Analysis of Microarray Databases.

Tzu-Yang Weng, Chih-Yang Wang, Yu-Hsuan Hung, Wei-Ching Chen, Yi-Ling Chen, Ming-Derg Lai
Author Information
  1. Tzu-Yang Weng: Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  2. Chih-Yang Wang: Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  3. Yu-Hsuan Hung: Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  4. Wei-Ching Chen: Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  5. Yi-Ling Chen: Department of Senior Citizen Services Management, Chia Nan University of Pharmacy and Science, Tainan, Taiwan.
  6. Ming-Derg Lai: Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
PMID: 27513329 DOI: 10.1371/journal.pone.0161007

Abstract

Thrombospondin 1 and thrombospondin 2 (THBS1 and THBS2) share similar multifunctional domains, and are known to be antiangiogenic. However, the expression pattern of THBS1 and THBS2 is different, and the specific role of THBS2 in different subtypes of lung cancer remains largely unclear. To evaluate the significance of THBS1 and THBS2 in the development of lung cancer, the present study performed a microarray-based systematic-analysis to determine the transcript levels of thrombospondins and their relation to the prognosis in lung cancer. THBS1 was in general underexpressed in lung cancer; in contrast, mRNA levels of THBS2 were markedly overexpressed in a number of datasets of non-small cell lung carcinoma (NSCLC), including lung adenocarcinoma (AC) and squamous cell carcinoma. Similar expression pattern of THBS1 and THBS2 was verified in pulmonary AC cell lines with real-time PCR analysis. The survival of lung AC patients with high THBS2 mRNA expression levels was poorer than patients with low levels of expression of THBS2. In a microarray-based analysis, genes coexpressed with THBS1 or THBS2 were determined. Pulmonary AC patients with a high expression level of sevenTSHB1-coexpressed genes (CCL5, CDH11, FYB, GZMK, LA-DQA1, PDE4DIP, and SELL) had better survival rates than those with a low expression level. Patients with a high expression of seven TSHB2-coexpressed genes (CHI3L1, COL5A2, COL11A1, FAP, MXRA5, THY1, and VCAN) had poor survival rates. Downregulation of VCAN and THBS2 with shRNA inhibited the cell proliferation in the A549 cell line. In summary, THBS1 functions as a tumor suppressor in lung adenocarcinoma. However, THBS2 may play a double-edged role in the progression of lung AC, i.e. anti-angiogenic and oncogenic function. Further study on the mechanism underlying the activity of THBS2 is warranted to have further implications for cancer diagnosis and treatment of pulmonary AC.

References

  1. EMBO J. 2001 Jun 1;20(11):2631-40 [PMID: 11387198]
  2. Anticancer Res. 2010 Mar;30(3):713-8 [PMID: 20392988]
  3. J Biol Chem. 2000 Nov 17;275(46):36358-68 [PMID: 10964924]
  4. Cardiovasc Res. 2009 Aug 1;83(3):566-74 [PMID: 19414528]
  5. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14888-93 [PMID: 10611308]
  6. J Immunol. 2007 May 1;178(9):5930-9 [PMID: 17442977]
  7. Cancer Treat Rev. 2014 May;40(4):558-66 [PMID: 24176790]
  8. Cancer Res. 1997 Feb 1;57(3):396-9 [PMID: 9012463]
  9. Clin Transl Oncol. 2013 Nov;15(11):897-902 [PMID: 23463593]
  10. Nat Rev Clin Oncol. 2015 Sep;12(9):511-26 [PMID: 25963091]
  11. Cell Mol Life Sci. 2008 Mar;65(5):672-86 [PMID: 18193164]
  12. Neoplasia. 2007 Feb;9(2):166-80 [PMID: 17356713]
  13. Blood. 2005 Dec 1;106(12):3860-6 [PMID: 16118322]
  14. Cancer Biomark. 2015;15(5):645-51 [PMID: 26406953]
  15. BMC Cancer. 2015 Aug 15;15:590 [PMID: 26275425]
  16. Genes Cancer. 2010 Jan;1(1):12-25 [PMID: 21779425]
  17. Clin Cancer Res. 2001 Sep;7(9):2826-31 [PMID: 11555600]
  18. J Cell Mol Med. 2002 Jan-Mar;6(1):1-12 [PMID: 12003665]
  19. J Cell Commun Signal. 2009 Dec;3(3-4):189-200 [PMID: 19798599]
  20. Clin Cancer Res. 1998 Jul;4(7):1785-8 [PMID: 9676856]
  21. J Immunol. 2006 Sep 15;177(6):3534-41 [PMID: 16951312]
  22. Cancer. 2010 Sep 1;116(17 ):4114-21 [PMID: 20564116]
  23. Mediators Inflamm. 2011;2011:296069 [PMID: 21765615]
  24. Nature. 2002 Dec 19-26;420(6917):860-7 [PMID: 12490959]
  25. Oncol Rep. 2009 Aug;22(2):279-83 [PMID: 19578767]
  26. Oncol Rep. 2006 Nov;16(5):981-8 [PMID: 17016581]
  27. Oncol Rep. 2013 Dec;30(6):2733-40 [PMID: 24101104]
  28. Int J Biochem Cell Biol. 2004 Jun;36(6):961-8 [PMID: 15094109]
  29. Adv Exp Med Biol. 2015;833:9-14 [PMID: 25298262]
  30. Br J Haematol. 2007 Sep;138(6):756-60 [PMID: 17760807]
  31. J Invest Dermatol. 2003 Dec;121(6):1536-43 [PMID: 14675207]
  32. PLoS One. 2012;7(4):e35157 [PMID: 22509397]
  33. PLoS One. 2013 Sep 16;8(9):e74250 [PMID: 24066126]
  34. Cell Mol Life Sci. 2008 Mar;65(5):700-12 [PMID: 18193162]
  35. Am J Respir Cell Mol Biol. 1997 Sep;17(3):353-60 [PMID: 9308922]
  36. Cytokine Growth Factor Rev. 2000 Mar-Jun;11(1-2):59-69 [PMID: 10708953]
  37. Lung Cancer. 2002 May;36(2):143-50 [PMID: 11955648]
  38. Annu Rev Med. 2014;65:185-202 [PMID: 24188664]
  39. Sci Rep. 2015 Dec 04;5:17566 [PMID: 26634905]
  40. Curr Genomics. 2008 Dec;9(8):525-34 [PMID: 19516959]
  41. PLoS One. 2013 Dec 18;8(12):e82241 [PMID: 24367507]
  42. J Int Med Res. 2009 Mar-Apr;37(2):551-6 [PMID: 19383251]
  43. J Cancer Res Clin Oncol. 2013 Sep;139(9):1523-8 [PMID: 23835897]
  44. ISRN Biochem. 2014 Apr 10;2014:351959 [PMID: 25937967]
  45. Hum Pathol. 2005 Jan;36(1):44-50 [PMID: 15712181]
  46. Nat Protoc. 2009;4(1):44-57 [PMID: 19131956]
  47. PLoS One. 2012;7(2):e31906 [PMID: 22363766]
  48. Blood. 2002 Jan 15;99(2):538-45 [PMID: 11781236]
  49. Oncotarget. 2016 Jan 5;7(1):995-1013 [PMID: 26654942]
  50. Mol Cancer. 2014 Sep 28;13:225 [PMID: 25262009]

MeSH Term

Adenocarcinoma
Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung
Carcinoma, Squamous Cell
Databases, Factual
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Humans
Lung Neoplasms
Neoplasm Staging
Prognosis
Real-Time Polymerase Chain Reaction
Survival Rate
Thrombospondin 1
Thrombospondins

Chemicals

Biomarkers, Tumor
Thrombospondin 1
Thrombospondins
thrombospondin 2
thrombospondin-1, human
Journal Article

Word Cloud

Created with Highcharts 10.0.0THBS2lungTHBS1expressionACcancercelllevelssurvivalpatientshighgenesHoweverpatterndifferentrolestudymicroarray-basedmRNAcarcinomaadenocarcinomapulmonaryanalysislowlevelratesVCANThrombospondin1thrombospondin2sharesimilarmultifunctionaldomainsknownantiangiogenicspecificsubtypesremainslargelyunclearevaluatesignificancedevelopmentpresentperformedsystematic-analysisdeterminetranscriptthrombospondinsrelationprognosisgeneralunderexpressedcontrastmarkedlyoverexpressednumberdatasetsnon-smallNSCLCincludingsquamousSimilarverifiedlinesreal-timePCRpoorercoexpresseddeterminedPulmonarysevenTSHB1-coexpressedCCL5CDH11FYBGZMKLA-DQA1PDE4DIPSELLbetterPatientssevenTSHB2-coexpressedCHI3L1COL5A2COL11A1FAPMXRA5THY1poorDownregulationshRNAinhibitedproliferationA549linesummaryfunctionstumorsuppressormayplaydouble-edgedprogressionieanti-angiogeniconcogenicfunctionmechanismunderlyingactivitywarrantedimplicationsdiagnosistreatmentDifferentialExpressionPatternLungCancer:ClinicalOutcomeSystematic-AnalysisMicroarrayDatabases

Similar Articles

Cited By